Through a dual-modality molecular imaging approach, this research provides novel insight into anti-PD-1 therapy’s effects on PD-L1 expression and glucose metabolism in normal organs of NSCLC patients, demonstrating that these parameters remain stable post-treatment. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.